Microsoft Word - eTOXNewsletter18v9 - Quantitative research - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-03-30 09:11:20 Drug discovery Clinical research Pharmaceutical industry Toxicology ETOX Clinical trials Quantitative structureactivity relationship Pharmacovigilance Drug development Pre-clinical development Validation Food and Drug Administration		Microsoft Word - eTOXNewsletter18v9 Add to Reading List Source URL: www.etoxproject.eu Download Document from Source Website File Size: 254,60 KB Share Document on Facebook

	Demonstrating the use of statistical-based QSAR methodologies to predict the bacterial mutagenicity assay Glenn J. Myatt () Leadscope, Inc. DocID: 1rtjD - View Document
	Development of Improved QSAR Models for Predicting A-T Base Pair Mutations Lidiya Stavitskaya, Barbara L. Minnier, R. Daniel Benz, and Naomi L. Kruhlak FDA Center for Drug Evaluation and Research (CDER), 10903 New Hampsh DocID: 1qXNs - View Document
	Abstract # 2640 Importance of Comprehensive Reporting of (Q)SAR Assessments Under ICH M7 Lidiya Stavitskaya, Barbara L. Minnier, Mark W. Powley, Neil R. Hartman, and Naomi L. Kruhlak FDA Center for Drug Evaluation and R DocID: 1qPyc - View Document
	Implementation of ICH M7 Recommended (Q)SAR Analyses Naomi Kruhlak, PhD Lidiya Stavitskaya, PhD Chemical Informatics Program Division of Applied Regulatory Science DocID: 1qy77 - View Document
	Development of Improved Salmonella Mutagenicity QSAR Models Using Structural Fingerprints of Known Toxicophores Lidiya Stavitskaya, Barbara L. Minnier, R. Daniel Benz, Naomi L. Kruhlak FDA Center for Drug Evaluation and DocID: 1qmH7 - View Document